Scholarlink

<p>Dual pancreatic cancers, either synchronous or metachronous in presentation, are a rare occurrence. It remains unclear if these lesions are clonally related or independently occurring primary malignancies. Herein we present a cohort (N = 22) with dual pancreatic ductal adenocarcinoma (PDAC) tumors to resolve previously conflicting reports and interrogate the underlying biological and clinical characteristics of this patient population. Next-generation sequencing of paired lesions (N = 10) revealed that while most dual PDAC are clonally related, independently occurring lesions do occur, irrespective of the interval between lesions. Integrated clinical, genomic, and histopathological analyses revealed a high frequency of lymph node-negative, intraductal papillary mucinous neoplasm (IPMN)-associated cancers, <i>KRAS</i> and/or <i>SMAD4</i> wild-type tumors, and classical subtype by immunohistochemistry, all collectively associated with more favorable outcomes. Acknowledging the highly selected nature of this cohort, isolated intrapancreatic metastases demonstrate a more indolent biology and these patients may benefit from personalized management approaches beyond traditional paradigms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual pancreatic carcinomas: clonally related or independent primaries?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月8日

查看全文
  • Joshua D. Schoenfeld,
  • Vignesh Ravichandran,
  • Zeynep Tarcan,
  • Hulya Sahin-Ozkan,
  • Allison L. Richards,
  • Nadeem Bilani,
  • Joanne F. Chou,
  • Catherine A. O’Connor,
  • David McManamon,
  • Anna M. Varghese,
  • Fergus Keane,
  • Michael I. D’Angelica,
  • William R. Jarnagin,
  • Jeffrey Drebin,
  • Diane Reidy-Lagunes,
  • Alice C. Wei,
  • Sree B. Chalasani,
  • Fiyinfolu Balogun,
  • Wungki Park,
  • Kenneth H. Yu,
  • Kevin Soares,
  • Mark T. A. Donoghue,
  • Christine Iacobuzio-Donahue,
  • Zsofia K. Stadler,
  • Marinela Capanu,
  • Olca Basturk,
  • Eileen M. O’Reilly

摘要

Dual pancreatic cancers, either synchronous or metachronous in presentation, are a rare occurrence. It remains unclear if these lesions are clonally related or independently occurring primary malignancies. Herein we present a cohort (N = 22) with dual pancreatic ductal adenocarcinoma (PDAC) tumors to resolve previously conflicting reports and interrogate the underlying biological and clinical characteristics of this patient population. Next-generation sequencing of paired lesions (N = 10) revealed that while most dual PDAC are clonally related, independently occurring lesions do occur, irrespective of the interval between lesions. Integrated clinical, genomic, and histopathological analyses revealed a high frequency of lymph node-negative, intraductal papillary mucinous neoplasm (IPMN)-associated cancers, KRAS and/or SMAD4 wild-type tumors, and classical subtype by immunohistochemistry, all collectively associated with more favorable outcomes. Acknowledging the highly selected nature of this cohort, isolated intrapancreatic metastases demonstrate a more indolent biology and these patients may benefit from personalized management approaches beyond traditional paradigms.